

30333, ATTN: PRA (0920-0666)

### **Home Dialysis Center Practices Survey**

Form Approved OMB No. 0920-0666 Exp. Date: 11/30/2019 www.cdc.gov/nhsn

Complete this survey as described in the **Dialysis Event Protocol**.

**Instructions:** This survey is only for dialysis centers that **do not** provide in-center hemodialysis. If your center performs in-center hemodialysis, please complete the <u>Outpatient Dialysis Center Practices Survey</u>. Complete one survey per center. Surveys are completed for the current year. It is strongly recommended that the survey is completed in February of each year by someone who works in the center and is familiar with current practices within the center. Complete the survey based on the actual practices at the center, not necessarily the center policy, if there are differences. Please submit your responses to the questions in this survey electronically by logging into your NHSN facility.

| *required to save as complete  |  |  |   |  |  |
|--|--|--|---|--|--|
| Facility   | Facility ID #:         *Survey Year:   |  |   |  |  |
| *ESRD Network #:   |  |  |   |  |  |
| A. Dialysis Center Information   |  |  |   |  |  |
| A.1. Ge  |  |  |   |  |  |
| *1.  | What is the ownership of your dialysis center? (choose one)  |  |   |  |  |
|  | ☐ Government ☐ Not for profit  | ☐ For profit                                   |   |  |  |
| *2.  | What is the location/hospital affiliation of your dialysis cen-  | ter? (choose one)                              |   |  |  |
|  | ☐ Freestanding ☐ Hospital based  | $\square$ Freestanding but owned by a hospital |   |  |  |
| *3.  | Is your facility accredited by an organization other than CN a. If yes, specify (choose one)   | MS? □ Yes □ N                                  | 0 |  |  |
|  | ☐ Joint Commission ☐ National Dialysis ☐ Commission (NDAC  | Accreditation                                  | _ |  |  |
| *4.  | a. What types of dialysis services does your center offer?   | (select all that apply)                        |   |  |  |
|  | ☐ Peritoneal dialysis ☐ Home hemodialysis  |  |   |  |  |
|  | b. What patient population does your center serve? (selec  | et one)  |   |  |  |
|  | ☐ Adult only ☐ Pediatric only  | ☐ Mixed: adult and pediatric                   |   |  |  |
| *5.  | Is your center part of a group or chain of dialysis centers?   | □ Yes □ N                                      | 0 |  |  |
|  | a. If yes, what is the name of the group or chain?   |  |   |  |  |
| *6.  | Do you (the person primarily responsible for completing the the dialysis center or in the homes of patients cared for by   | nis survey) perform patient care in ☐ Yes ☐ N  | 0 |  |  |
| *7.  | Does your center provide dialysis services within long-terr  |  | О |  |  |
|  | assisted dialysis in nursing homes or skilled nursing facilities; not long-term acute care   |  |   |  |  |
|  | hospitals)?  |  |   |  |  |
|  | a. If yes, in how many long-term care facilities?  |  | _ |  |  |
| A.2. Su  | urveillance  |  |   |  |  |
| *8.  | Which of the following infections in your peritoneal dialysis (select all that apply)  | s patients does your center routinely track?   |   |  |  |
|  |  | nel infection   Other (specify)                | _ |  |  |
| *9.  | Which of the following events in your home hemodialysis (select all that apply)  | patients does your center routinely track?     |   |  |  |
|  | ☐ Bloodstream infection ☐ Needle/access dislodgeme   | ent   Other (specify)                          | _ |  |  |
|  | □ Vascular access site □ Air embolism  | m  |   |  |  |
| Assuranc   | infection  | dline separation                               |   |  |  |
| Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). |  |  |   |  |  |
| Public reporting burden of this collection of information is estimated to average 25 minutes per response, including the time for reviewing instructions, searching existing   |  |  |   |  |  |
| data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or   |  |  |   |  |  |
|  | any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA |  |   |  |  |

CDC 57.507 (Back) Rev 0, v8.6



| *10.     | If a patient from your center was hospitalized, how often is your center able to determine if a bloodstream infection contributed to their hospital admission?  □ Always □ Often □ Sometimes □ Rarely □ Never □ N/A – not pursued |  |
|----------|---|--|
| *11.     | How often is your center able to obtain a patient's microbiology lab records from a hospitalization?  □ Always □ Often □ Sometimes □ Rarely □ Never □ N/A – not pursued   |  |
| (applies | e respond to the following questions based on information from your center for the first week of February s to current or most recent February relative to current date).   |  |
|          | ent and staff census  |  |
| *12.     | Was your center operational during the first week of February? □ Yes □ No   |  |
| *13.     | How many dialysis <b>PATIENTS</b> were assigned to your center during the first week of February?   |  |
|          | Of these, indicate the number who received:   |  |
|          | a. Peritoneal dialysis:   |  |
|          | b. Home hemodialysis:   |  |
| *14.     | How many <b>PATIENT CARE</b> staff (full time, part time, or affiliated with) worked in your center during the first week of February? <i>Include only staff who had direct contact with dialysis patients or equipment</i> :     |  |
|          | Of these, how many were in each of the following categories?  |  |
|          | a. Nurse/nurse assistant:   |  |
|          | b. Dialysis patient-care technician:  |  |
|          | c. Dialysis biomedical technician:  |  |
|          | d. Social worker:   |  |
|          | e. Dietitian:   |  |
|          | f. Physicians/physician assistant:  |  |
| ĺ        | g. Nurse practitioner:  |  |
|          | h. Other:   |  |
| C. Vac   | cines   |  |
| *15.     | Of the <u>dialysis patients</u> counted in question 13, how many received:  |  |
|          | a. At least 3 doses of hepatitis B vaccine (ever)?  |  |
|          | b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?   |  |
|          | c. At least one dose of pneumococcal vaccine (ever)?  |  |
| *16.     | Of the home hemodialysis patients counted in question 13b, how many received:   |  |
|          | a. At least 3 does of hepatitis B vaccine (ever)?   |  |
|          | b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?   |  |
|          | c. At least one dose of pneumococcal vaccine (ever)?  |  |
| *17.     | Of the patient care staff members counted in question 14, how many received:  |  |
|          | <ul><li>a. At least 3 doses of hepatitis B vaccine (ever)?</li><li>b. The influenza (flu) vaccine for the <u>current/most recent</u> flu season?</li></ul>  |  |
| *18.     |   |  |
| 10.      | Which type of pneumococcal vaccine does your center offer to <b>patients</b> ? (choose one)  ☐ Polysaccharide (i.e., PPSV23) only   |  |
|          | ☐ Conjugate (e.g., PCV13) only  |  |
|          | ☐ Both polysaccharide & conjugate   |  |
|          | ☐ Neither offered   |  |



| D. Scre  | ening  |  |  |  |
|----------|--|--|--|--|
| *19.     | Does your center routinely screen patients for hepatitis B surface antigen (HBsAg) upon initiation of care?  |  |  |  |
|          | a. Peritoneal patients ☐ Yes ☐ No  |  |  |  |
|          | b. Home hemodialysis patients $\square$ Yes $\square$ No   |  |  |  |
| *20.     | Does your center routinely screen patients for <b>hepatitis C</b> antibody (anti-HCV) upon initiation of care?   |  |  |  |
|          | a. Peritoneal patients ☐ Yes ☐ No  |  |  |  |
|          | b. Home hemodialysis patients $\square$ Yes $\square$ No   |  |  |  |
| *21.     | Does your center routinely screen patients for latent tuberculosis infection (LTBI) upon initiation of care?   |  |  |  |
|          |  |  |  |  |
|          | a. Peritoneal patients ☐ Yes ☐ No  |  |  |  |
|          | b. Home hemodialysis patients ☐ Yes ☐ No   |  |  |  |
| E. Prev  | vention Activities   |  |  |  |
| *22.     | Is your center actively participating in any of the following prevention initiatives (select all that apply):  |  |  |  |
|          | ☐ CDC Making Dialysis Safer for Patients Coalition – facility-level participation  |  |  |  |
|          | ☐ CDC Making Dialysis Safer for Patients Coalition – corporate- or other organization-level participation  |  |  |  |
|          | <ul> <li>The Standardizing Care to improve Outcomes in Pediatric End Stage Renal Disease (SCOPE)</li> <li>Collaborative Peritoneal Dialysis Catheter-related Infection Project</li> </ul>                          |  |  |  |
|          | •  |  |  |  |
|          | <ul> <li>□ SCOPE Collaborative Hemodialysis Access-related Infection Project</li> <li>□ None of the above</li> </ul>   |  |  |  |
| *00      |  |  |  |  |
| *23.     | In the past year, has your center's medical director participated in a leadership or educational ☐ Yes ☐ No activity as part of the American Society of Nephrology's (ASN) Nephrologists Transforming              |  |  |  |
|          | Dialysis Safety (NTDS) Initiative?   |  |  |  |
| F. Perit | toneal Dialysis Catheters  |  |  |  |
| *24.     | For <b>peritoneal dialysis catheters</b> , is antimicrobial ointment routinely applied to the  |  |  |  |
|          | exit site during dressing change?  |  |  |  |
|          | a. If yes, what type of ointment is most commonly used? (select one)   |  |  |  |
|          | ☐ Gentamicin ☐ Bacitracin/polymyxin B (e.g., Polysporin®)  |  |  |  |
|          | <ul><li>☐ Mupirocin</li><li>☐ Bacitracin/neomycin/polymyxin B (triple antibiotic)</li><li>☐ Povidone-iodine</li><li>☐ Bacitracin/gramicidin/polymyxin B (Polysporin® Triple)</li></ul>                             |  |  |  |
|          | ☐ Povidone-iodine ☐ Bacitracin/gramicidin/polymyxin B (Polysponn® Triple)  |  |  |  |
| C Voc    |  |  |  |  |
|          | cular Access   |  |  |  |
|          | eneral Vascular Access Information   |  |  |  |
| *25.     | Of the home hemodialysis patients from question 13b, how many received dialysis through each of the  |  |  |  |
|          | following access types during the first week of February?  |  |  |  |
|          | a. AV fistula:   |  |  |  |
|          | b. AV graft:<br>c. Tunneled central line:  |  |  |  |
|          | d. Nontunneled central line:   |  |  |  |
|          | e. Other vascular access device (e.g., catheter-graft hybrid):   |  |  |  |
| G 2 Ar   |  |  |  |  |
|          | teriovenous (AV) Fistulas or Grafts  |  |  |  |
| *26.     | Before prepping the fistula or graft site for rope-ladder cannulation, what is the site most often <u>cleansed</u> with?  □ Soap and water □ Alcohol-based hand rub □ Antiseptic wipes □ Other, specify: □ Nothing |  |  |  |
|          |  |  |  |  |



| *27.   | Before rope-ladder cannulation of a fistula or graft, what is the site most often prepped with? (select the one most commonly used)  |  |  |  |
|--------|--|--|--|--|
|        | □ Alcohol  |  |  |  |
|        | ☐ Chlorhexidine without alcohol  |  |  |  |
|        | ☐ Chlorhexidine with alcohol (e.g., Chloraprep®, PDI Prevantics®)  |  |  |  |
|        | ☐ Povidone-iodine (or tincture of iodine)  |  |  |  |
|        | ☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol  |  |  |  |
|        | ☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol  |  |  |  |
|        | ☐ Other, specify:  |  |  |  |
|        | ☐ Nothing  |  |  |  |
|        | a. What form of this skin antiseptic is used to prep fistula/graft sites?  |  |  |  |
|        | ☐ Multiuse bottle (e.g., poured onto gauze) ☐ Pre-packaged swabstick/spongestick   |  |  |  |
|        | ☐ Pre-packaged pad ☐ Other, specify:   |  |  |  |
|        | □ N/A  |  |  |  |
| *28.   | How many of your fistula patients undergo buttonhole cannulation?  |  |  |  |
| *00    | □ All □ Most □ Some □ None   |  |  |  |
| *29.   | Is antimicrobial ointment (e.g. mupirocin) routinely used at buttonhole cannulation sites to $\Box$ Yes $\Box$ No prevent infection?   |  |  |  |
| G.3. H | emodialysis Catheters  |  |  |  |
| *30.   | Are patients who receive hemodialysis through a central venous catheter permitted in $\Box$ Yes $\Box$ No  |  |  |  |
|        | your home hemodialysis program?  |  |  |  |
| *31.   | Before accessing the hemodialysis catheter, what are the <b>catheter hubs</b> most commonly prepped with? (select the one most commonly used)  |  |  |  |
|        | □ Alcohol  |  |  |  |
|        | ☐ Chlorhexidine without alcohol  |  |  |  |
|        | ☐ Chlorhexidine with alcohol (e.g., Chloraprep®, PDI Prevantics®)  |  |  |  |
|        | ☐ Povidone-iodine (or tincture of iodine)  |  |  |  |
|        | ☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol  |  |  |  |
|        | ☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol  |  |  |  |
|        | ☐ Other, specify:  |  |  |  |
|        | ☐ Nothing  |  |  |  |
|        | a. What form of this antiseptic/disinfectant is used to prep the catheter hubs?  |  |  |  |
|        | ☐ Multiuse bottle (e.g., poured onto gauze)  |  |  |  |
|        | ☐ Pre-packaged swabstick/spongestick   |  |  |  |
|        | ☐ Pre-packaged pad   |  |  |  |
|        | ☐ Other, specify:  |  |  |  |
|        | □ N/A  |  |  |  |
| *32.   | Are catheter hubs routinely scrubbed after the cap is removed and before accessing the $\Box$ Yes $\Box$ No catheter (or before accessing the catheter via a needleless connector device, if one is used)? |  |  |  |
| *33.   | When the catheter dressing is changed, what is the exit site (i.e., place where the catheter enters the skin) most commonly prepped with? (select the one most commonly used)                              |  |  |  |
|        | ☐ Alcohol  |  |  |  |
|        | ☐ Chlorhexidine without alcohol  |  |  |  |
|        | ☐ Chlorhexidine with alcohol (e.g., Chloraprep®, PDI Prevantics®)  |  |  |  |
|        | □ Povidone-iodine (or tincture of iodine)  |  |  |  |
|        | ☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) without alcohol  |  |  |  |
|        | ☐ Sodium hypochlorite solution (e.g., ExSept®, Alcavis) followed by alcohol  |  |  |  |
|        | ☐ Other, specify:  |  |  |  |
|        | □ Nothing  |  |  |  |
|        | Li Notining  |  |  |  |



| ANNUAL LINE | a. What form of this antiseptic/disinfectant  | is used at the exit site?   | www.cac.gov/nnsn                 |
|-------------|---|---|----------------------------------|
|             | ☐ Multiuse bottle (e.g., poured onto g  |   |                                  |
|             | , , , ,   | · ·   |                                  |
|             | ☐ Pre-packaged swabstick/spongestic   | K   |                                  |
|             | ☐ Pre-packaged pad  |   |                                  |
|             | Other, specify:   | _   |                                  |
|             | □ N/A   |   |                                  |
|             |   |   |                                  |
|             | emodialysis Catheters (continued)   |   |                                  |
| *34.        | For <b>hemodialysis catheters</b> , is antimicrobial oi   | ,   |                                  |
|             | □ Yes □No □   | N/A – chlorhexidine-impregnated   | I dressing is routinely used     |
|             | <ul> <li>a. If yes, what type of ointment is most con</li> </ul>  | nmonly used? (select one)   |                                  |
|             | ☐ Bacitracin/gramicidin/polymyxin B (   | Polysporin® Triple)   | ☐ Gentamicin                     |
|             | ☐ Bacitracin/polymyxin B (e.g., Polys   | oorin®)   | ☐ Mupirocin                      |
|             | ☐ Bacitracin/neomycin/polymyxin B (t  | riple antibiotic)   | □ Povidone-iodine                |
|             | ☐ Other, specify:   | _   |                                  |
| *35.        | Are antimicrobial lock solutions used to <b>prevent</b>   | hemodialysis catheter infections  | ?                                |
|             | -   | es, for some catheter patients  | □ No                             |
|             | a. If yes, which lock solution is most comr   | nonly used? (select one)  |                                  |
|             | ☐ Sodium citrate ☐ Taurolidine  |   |                                  |
|             | ☐ Gentamicin ☐ Ethanol  |   |                                  |
|             | ☐ Vancomycin ☐ Multi-compo  | nent lock solution or other, specif   | iy:                              |
| *36.        | Are needleless closed connector devices (e.g., hemodialysis catheters?  | Tego®, Q-Syte™) used on your p  | atients' □ Yes □No               |
| *37.        | Are any of the following routinely used for your h  | emodialysis catheter patients? (s   | select all that apply)           |
|             | Chlorhexidine dressing (e.g., Biopatch®, Te   | •   | □ Yes □No                        |
|             | Other antimicrobial dressing (e.g., silver-im   |   | □ Yes □No                        |
|             | Antiseptic-impregnated catheter cap/port protector:   |   |                                  |
|             | 3M™ Curos™ Disinfecting Port Prote  |   | □ Yes □No                        |
|             | ClearGuard® HD end caps   |   | □ Yes □No                        |
|             | Antimicrobial-impregnated hemodialysis car  | heters  | □ Yes □No                        |
| *38.        | Does your center provide hemodialysis catheter home?  |   | r changing catheter dressings at |
|             | ☐ Yes, routinely for all or most ☐ Yes, o patients with a catheter ☐ catheter   | nly for select patients with a $\Box$   | No                               |
| *39.        | a. Does your center educate patients with hemothe best response)  | dialysis catheters on how to show   | ver with the catheter? (select   |
|             | ☐ Yes, routinely for all or most patients with a catheter   | <ul> <li>No, patients with hemodi<br/>instructed against showering</li> </ul> |                                  |
|             | $\hfill \square$ Yes, only for select patients with a catheter  | <ul> <li>No, education and instruction this topic</li> </ul>                  | ctions are not provided          |
|             | <ul> <li>b. Does your center provide hemodialysis<br/>Shower Shield®, Cath Dry™) to allow th</li> </ul>                             |   | e catheter cover (e.g.,          |
|             | <ul><li>☐ Yes, routinely for all or most patients with</li><li>☐ Yes, only for select patients with a cather</li><li>☐ No</li></ul> |   |                                  |



| Comments:  |  |
|--|--|
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
| Disclaimer: Use of trade names and commercial sources is for identification only and does not imply endorsement.   |  |
| Discialiner. Use of trade frames and commercial sources is for identification only and does not imply endotsement. |  |